 |
|
Ruptured Arteriovenous Malformation Complicating Thrombolytic Therapy With Tissue Plasminogen Activator
Jacqueline Proner, MD;
Bruce R. Rosenblum, MD;
Allen Rothman, MD
Arch Neurol. 1990;47(1):105-106.
Abstract
• It is thought that the clot-specific activity of tissue plasminogen activator, used in the treatment of acute myocardial infarction, makes bleeding complications less common than does the use of either streptokinase or urokinase. The incidence of intracerebral hemorrhage complicating the use of tissue plasminogen activator has been estimated to be 0.68%. This is a report of the rupture of an intracranial arteriovenous malformation complicating the use of tissue plasminogen activator therapy. Theories for the mechanism of hemorrhage in this instance are presented, as are suggestions for future use of the enzyme.
Author Affiliations
From the Department of Internal Medicine, New Rochelle (NY) Hospital Medical Center (Dr Proner), and the Department of Neurosurgery, Mount Sinai Medical Center, New York, NY (Drs Rosenblum and Rothman).
Footnotes
Accepted for publication May 22, 1989.
Reprint requests to 1160 Fifth Ave, Suite 106, New York, NY 10029 (Dr Rosenblum).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
De Keyser et al.
Stroke 2007;38:2612-2618.
ABSTRACT
| FULL TEXT
Classification and Pathogenesis of Cerebral Hemorrhages After Thrombolysis in Ischemic Stroke
Trouillas and von Kummer
Stroke 2006;37:556-561.
ABSTRACT
| FULL TEXT
|
